Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design
Tóm tắt
Từ khóa
Tài liệu tham khảo
Shen, 2007, Molecular targeted therapy for advanced hepatocellular carcinoma, Target Oncol, 2, 199, 10.1007/s11523-007-0058-1
Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7
Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134
Llovet, 2003, Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047
Llovet, 1999, Natural history of untreated nonsurgical hepatocellular carcinoma: rational for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002/hep.510290145
Yeung, 2005, Natural history of untreated nonsurgical hepatocellular carcinoma, Am J Gastroenterol, 100, 1995, 10.1111/j.1572-0241.2005.00229.x
Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011
Kao, 2005, Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia, Liver Int, 25, 696, 10.1111/j.1478-3231.2005.01139.x
Iizuka, 2002, Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method, Cancer Res, 62, 3939
Kim, 2003, Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma, Clin Cancer Res, 9, 5493
Boyault, 2007, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, 45, 42, 10.1002/hep.21467
Poon, 2004, Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome, Liver Transpl, 10, S39, 10.1002/lt.20040
Jaeck, 2004, Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview, Liver Transpl, 10, S58, 10.1002/lt.20041
Makuuchi, 2008, Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan, Hepatol Res, 38, 37, 10.1111/j.1872-034X.2007.00216.x
Llovet, 2008, Novel advancements in the management of hepatocellular carcinoma in 2008, J Hepatol, 48, S20, 10.1016/j.jhep.2008.01.022
2006
Whitehead, 2002
Sarin, 2006, High dose vitamin K3 infusion in advanced hepatocellular carcinoma, J Gastroenterol Hepatol, 21, 1478, 10.1111/j.1440-1746.2006.04383.x
Chow, 2002, High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial, Hepatology, 36, 1221, 10.1053/jhep.2002.36824
Yuen, 2002, A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma, Hepatology, 36, 687, 10.1053/jhep.2002.35071
Ishikawa, 2001, Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma, J Gastroenterol Hepatol, 16, 452, 10.1046/j.1440-1746.2001.02352.x
Liu, 2000, Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study, Am J Gastroenterol, 95, 218, 10.1111/j.1572-0241.2000.01688.x
Becker, 2007, Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study, Hepatology, 45, 9, 10.1002/hep.21468
Dimitroulopoulos, 2007, Long acting octreotide in the treatment of advanced hepatocellular carcinoma and overexpression of somatostatin receptors: randomized placebo-controlled trial, World J Gastroenterol, 13, 3164, 10.3748/wjg.v13.i23.3164
Barbare, 2005, Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma, J Clin Oncol, 23, 4338, 10.1200/JCO.2005.05.470
Barbare, 2005, Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC), vol. 23, 4036
Villa, 2001, Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors, Br J Cancer, 84, 881, 10.1054/bjoc.2000.1534
Grimaldi, 1998, Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial, J Clin Oncol, 16, 411, 10.1200/JCO.1998.16.2.411
Kouroumalis, 1998, Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study, Gut, 42, 442, 10.1136/gut.42.3.442
Yamanaka, 1997, Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma, Cancer, 79, 1509, 10.1002/(SICI)1097-0142(19970415)79:8<1509::AID-CNCR10>3.0.CO;2-1
Chen, 2006, Hepatitis B and C-related hepatocellular carcinomas yield different clinical features and prognosis, Eur J Cancer, 42, 2524, 10.1016/j.ejca.2006.06.007
Belsley, 1980
Trevisani, 2007, Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance, Am J Gastroenterol, 102, 1022, 10.1111/j.1572-0241.2007.01100.x
Poon, 2002, Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective, Ann Surg, 235, 466, 10.1097/00000658-200204000-00004
Henderson, 2003, AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement, HPB (Oxford), 5, 243, 10.1080/13651820310015833
Wildi, 2004, Critical evaluation of the different staging systems for hepatocellular carcinoma, Br J Surg, 91, 400, 10.1002/bjs.4554
Georgiades, 2006, Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization, J Vasc Interv Radiol, 17, 1619, 10.1097/01.RVI.0000236608.91960.34
Guglielmi, 2008, Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response, Am J Gastroenterol, 103, 597, 10.1111/j.1572-0241.2007.01604.x
Cammà, 2008, Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems, Aliment Pharmacol Ther, 28, 62, 10.1111/j.1365-2036.2008.03692.x
Collette, 2008, Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials, Ann Oncol, 19, 1117, 10.1093/annonc/mdn030
Pawlik, 2004, Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma, J Gastrointest Surg, 8, 794, 10.1016/j.gassur.2004.06.013
Cantarini, 2006, Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma, Am J Gastroenterol, 101, 91, 10.1111/j.1572-0241.2006.00364.x